This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

Semaglutide Sodium and Acetate: Why the Salt Form Matters

FDA never called the salt forms dangerous; it said nobody has shown they are the same drug, and in drug law that settles it.

A pharmacist's bench with unlabeled glass vials and a powder scale beside a closed reference binder, lit by soft daylight.

On April 27, 2023, the Food and Drug Administration told the National Association of Boards of Pharmacy that it had thought about a particular chemical and could not come up with a reason for anyone to be using it. The chemical was semaglutide sodium, along with its cousin semaglutide acetate, and the use was compounding: pharmacies making their own versions of Ozempic and Wegovy. FDA said it was “not aware of any basis” for compounding with either salt that would satisfy federal rules on which raw ingredients compounders may use. That is agency language for no (a very polite no, but agencies are rarely rude in writing).

So here is the plain answer. Semaglutide sodium is semaglutide with a sodium group added, and semaglutide acetate is the same idea with an acetate group. The FDA-approved products, Ozempic and Wegovy, contain neither. They contain semaglutide base, the specific form that went through clinical trials and regulatory review. FDA’s position is that the salts are different active ingredients from the base, that it knows of no lawful way to compound with them under either section 503A or 503B of the law, and that it lacks information showing the salts share the base’s chemical and pharmacologic properties. No clinical studies exist confirming that the salts produce the same effects, absorption or safety profile as the base.

Why semaglutide sodium counts as a different ingredient

The intuitive view is that semaglutide sodium is semaglutide with a little extra on it. That is the wrong way to think about it. Or rather, it is chemically sort of right and legally completely wrong, which is the stranger and more useful version. Adding a sodium or acetate group changes the molecule’s weight and how it dissolves, and potentially how the body absorbs and clears it. FDA treats the result as a different active ingredient. Not a variant. A different drug.

It is a bit like a backup quarterback taking the field in the starter’s jersey. The name on the back is right. The stats belong to someone else.

Here is a made-up phone call, to make the problem concrete:

“Hi, I’d like to order some semaglutide.”

“We have semaglutide sodium.”

“Is that semaglutide?”

“It says semaglutide on the label.”

Everything in that conversation is in some sense true, and the problem is that the approval system does not run on things being in some sense true. It runs on a specific molecule having been tested in specific trials. The base form is that molecule. The salts are not.

The three doors into a compounding pharmacy

A compounder cannot simply buy any powder and turn it into injections. Federal law says a bulk drug substance has to come through one of three doors. It can have a monograph in the United States Pharmacopeia or National Formulary (a monograph being an official published standard for what the substance is and how pure it must be). It can be a component of an FDA-approved drug. Or it can appear on FDA’s list of approved bulk substances, known as the bulks list.

Semaglutide, in any form, has no monograph. So door one is shut for everybody. Semaglutide base gets through door two, because it is a component of Ozempic and Wegovy. Being a component of an approved drug is, in compounding law, the sexiest thing an ingredient can be (it gets you into rooms). The sodium and acetate salts are not components of any approved drug, and neither appears on the bulks list. That is zero doors out of three.

There was a separate argument that the shortage changed things. Wegovy and Ozempic sat on FDA’s drug shortage list for a while, and the shortage list is what let compounders make copies at scale in the first place (the site’s article on the shortage covers how a drug gets on and off). But FDA clarified that the shortage listing “does not authorize” compounding semaglutide sodium or any other salt. The shortage loosened one rule. It did not loosen the ingredient rule. And after May 22, 2025, FDA prohibited distribution of compounded semaglutide and tirzepatide altogether, which made the salt question smaller without quite making it go away.

Three ways to read the salt-form episode

There are, roughly, three ways to read why salts showed up in compounded semaglutide at all, and they get progressively less comfortable.

The first reading is about supply. Novo Nordisk makes all approved semaglutide through its own semi-recombinant process, and it does not sell semaglutide base, or any form of the active ingredient, to compounding pharmacies. So compounders had to source from somewhere else. Where exactly, and why the salts in particular, the facts here do not settle. Presumably salts were what some suppliers had (supply chains are not famous for their sense of regulatory nuance). That’s fine as an explanation of how it happened. It is not an explanation that FDA accepts as a legal basis for anything.

The second reading is about rules. Some compounders presumably read the shortage as broad permission, or read “semaglutide” on a supply label as the end of the inquiry. FDA said otherwise in April 2023, and its published materials now include a section titled “Salt forms should not be used to compound semaglutide.” The Mississippi Board of Pharmacy told its licensees in writing that salt compounding does not meet FDA’s bulk substance requirements and could draw action from FDA or the board. Some compounders substituted the salts anyway, including after the injectable shortage ended. A pharmacy that dispenses a salt-form product labeled just “semaglutide” faces misbranding findings, board complaints and civil liability from patients who were not told. I don’t know how many did. The incentive to call it semaglutide is obvious, I guess: that is the word people are looking for.

The third reading is the uncomfortable one. It is that nobody knows whether the salt matters medically, and that not knowing is the whole problem. The approval system is a machine for converting a molecule into evidence. Semaglutide base went through the machine. The salts did not. America’s Poison Centers put it plainly: “some compounding pharmacies used different salt forms of semaglutide, which differ from the active ingredient found in FDA-approved semaglutide products.” Using the salt rather than the base creates greater potential for instability and variability, which can raise the risk of side effects or of the drug simply not working. Could a given salt product behave identically? Maybe. Nobody has run the study.

What the absence of approval data actually means

Here is a made-up scenario, pushed past reason. Suppose “semaglutide plus a small attachment” counted as semaglutide. Then semaglutide sodium is fine, and semaglutide acetate is fine, and semaglutide potassium, and semaglutide with a slightly larger attachment, and eventually semaglutide with a second, different peptide bolted on, or whatever. At some point you have a new drug that has never met a patient, and its only credential is that its name starts the right way. The rule that salts are different ingredients is dumb-sounding right up until you try to draw the line anywhere else.

Which is why FDA’s actual statements are so modest. The agency did not say the salts are dangerous. It said it lacks information showing they share the base’s properties, and it was not aware of any basis to compound with them. It barely raised its voice. That understatement carries the entire regulatory weight, because the default in drug law is not “allowed until proven harmful.” It is “not allowed until shown.”

The evidence gap is real and not just rhetorical. (My own research for this piece included losing an argument with a reCAPTCHA box that would not let me read a scientific paper on the subject, so the absence of data on semaglutide salts is something I have experienced at a personal level, which is not the most heroic form of journalism.) Several legal analyses of semaglutide compounding contain no specific evidence about the sodium or acetate formulations at all. That is not a gap someone forgot to fill. There is just nothing there.

I suppose the cleanest way to put it is that the salt question was never really about sodium. It was about which version of a molecule had a file. The base had a file. The salts did not.

It was semaglutide in every way except the ones that had been checked.

Sources

  1. Semaglutide Salt Forms: Why the Base Matters
  2. Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
  3. FDA clarifies position on compounding semaglutide sodium
  4. GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner
  5. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
  6. FDA's Semaglutide Shortage Resolution: Legal Implications And Risks For Compounding Pharmacies | Legal 500
  7. Checking your browser - reCAPTCHA
  8. Checking your browser - reCAPTCHA
  9. Checking your browser - reCAPTCHA
  10. America's Poison Centers - GLP-1
  11. Semaglutide Sodium vs Base: What FDA Says and What to Ask
  12. Is your compounded semaglutide and tirzepatide safe?
  13. Businesses continue to sell compounded semaglutide, tirzepatide

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.

Read next